

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Administration for Children and Families**

[CFDA Number: 93.623]

**Announcement of the Intent to Award a Supplemental Grant to the National Safe Place Network in Louisville, KY****AGENCY:** Family and Youth Services Bureau, ACYF, ACF, HHS.**ACTION:** Notice.

**SUMMARY:** The Administration for Children and Families (ACF), Administration on Children, Youth and Families (ACYF), Family and Youth Services Bureau (FYSB) announces its intent to award a non-competitive supplemental grant in the amount of up to \$310,000 to the National Safe Place Network in Louisville, KY, to support and expand the grantee's activities under their award for the Runaway and Homeless Youth Training and Technical Assistance Center (RHYTTAC).

**DATES:** The proposed supplement is intended to support costs for the period of September 30, 2016, through September 29, 2017.

**FOR FURTHER INFORMATION CONTACT:** Ana Cody, Family and Youth Services Bureau, 330 C Street SW., Washington, DC 20024. Telephone: 202-205-8418 Email: [Ana.Cody@acf.hhs.gov](mailto:Ana.Cody@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The National Safe Place Network is the recipient agency of the RHYTTAC cooperative agreement that fulfills Section 342 of the Runaway and Homeless Youth (RHY) Act, which allows for grants to organizations to provide training and technical assistance to public and private entities that are eligible to receive grants under this title. The purpose of this agreement is for carrying out the programs, projects, or activities for which such grants are made. The original award was made as the result of a competition under ACF Funding Opportunity Announcement HHS-2012-ACF-ACYF-CY-0312.

The primary goal of the RHYTTAC program is to serve as a centralized, national Training and Technical Assistance (T&TA) resource for FYSB-funded RHY program grantees. Training and other resources are made available to assist grantees to improve the quality of their core services, build capacity to increase the number of youth served, and address the dynamic needs of the runaway and homeless youth population.

The total supplemental funding available for the proposed non-

competitive award would allow for the allocation of \$150,000 for T&TA to support 12 new Domestic Victims of Human Trafficking (DVHT) grantees and the allocation of \$160,000 for T&TA to support 8 new Transitional Living Program (TLP) demonstration program grantees.

The supplemental funding will be used to provide each grantee in the DVHT program with an on-site T&TA visit by RHYTTAC to collect information from a Human Trafficking Specific Capacity Assessment. The assessment and on-site observations will be used to create individualized action plans for each grantee to direct RHYTTAC's work with them for the remainder of their projects. In addition, RHYTTAC will facilitate discussions with human trafficking experts and coordinate a peer-exchange meeting to encourage grantees to build a cohesive working group. It will operate as a unit to ensure that all programs are functioning from the same baseline performance level. The proposed funding also will support new approaches and strategies to better serve Lesbian, Gay, Bisexual, Transgender, and Questioning (LGBTQ) youth and youth who are "aging out" of foster care.

A new, non-competitive application will be solicited from the National Safe Place Network. The application will receive an objective review by a panel using criteria related to the program's approach, objectives, outcomes and need for assistance, organizational profile, and an assessment of the proposed budget and budget justification.

**STATUTORY AUTHORITY:** The RHY and FYSB grantee is authorized by the RHY Act, 42 U.S.C. 5701-5752, as most recently amended by the Reconnecting Homeless Youth Act of 2008, Pub. L. 110-378, on October 8, 2008.

**Mary M. Wayland,**

*Senior Grants Policy Specialist, Division of Grants Policy, Office of Administration, Administration for Children and Families.*

[FR Doc. 2016-18502 Filed 8-3-16; 8:45 am]

**BILLING CODE 4182-04-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration**

[Docket No. FDA-2016-D-2268]

**Insanitary Conditions at Compounding Facilities; Draft Guidance for Industry; Availability****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Insanitary Conditions at Compounding Facilities." Drug products compounded under insanitary conditions could become contaminated and cause serious adverse events in patients, including death. FDA is issuing this draft guidance to assist compounding facilities in identifying insanitary conditions so that they can implement appropriate corrective actions, and to assist State regulatory agencies in understanding some examples of what FDA considers to be insanitary conditions.

**DATES:** Although you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by October 3, 2016.

**ADDRESSES:** You may submit comments as follows:

*Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <http://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <http://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <http://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

*Written/Paper Submissions*

Submit written/paper submissions as follows:

- Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA-305), Food

and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

**Instructions:** All submissions received must include the Docket No. FDA-2016-D-2268 for "Insanitary Conditions at Compounding Facilities." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <http://www.regulations.gov> or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <http://www.regulations.gov>. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <http://www.fda.gov/regulatoryinformation/dockets/default.htm>.

**Docket:** For access to the docket to read background documents or the electronic and written/paper comments received, go to <http://www.regulations.gov> and insert the docket number, found in brackets in the heading of this document, into the "Search" box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Submit written requests for single copies of the draft guidance to the Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration, 10001 New Hampshire Ave., Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002. Send one self-addressed adhesive label to assist that office in processing your requests. See the **SUPPLEMENTARY INFORMATION** section for electronic access to the draft guidance document.

**FOR FURTHER INFORMATION CONTACT:** Sara Rothman, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 5197, Silver Spring, MD 20993, 301-796-3110.

#### **SUPPLEMENTARY INFORMATION:**

#### **I. Background**

FDA is announcing the availability of a draft guidance for industry entitled "Insanitary Conditions at Compounding Facilities." Under section 501(a)(2)(A) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 351(a)(2)(A)), a drug is deemed to be adulterated if it has been prepared, packed, or held under insanitary conditions whereby it may have been contaminated with filth, or whereby it may have been rendered injurious to health. Drug products compounded under insanitary conditions could become contaminated and cause serious adverse events in patients, including death. Although sections 503A and 503B of the FD&C Act (21 U.S.C. 353a and 353b) provide exemptions for compounded drugs from specified provisions of the FD&C Act if certain conditions are met, neither section provides an exemption from section 501(a)(2)(A) of the FD&C Act. Any drug that is prepared, packed, or held under insanitary conditions is deemed to be adulterated under the FD&C Act, including drugs produced by a compounding facility.

Since the 2012 fungal meningitis outbreak associated with injectable drug products that a compounding facility produced and shipped across the country, FDA has identified insanitary conditions at many of the compounding facilities that it has inspected, and numerous compounding facilities have voluntarily recalled drug products intended to be sterile and temporarily or permanently ceased sterile operations as a result of these findings. However, FDA does not inspect the vast majority of compounding facilities in the United States because they generally do not register with FDA unless they elect to become outsourcing facilities. Therefore, FDA is often not aware of

these facilities and potential problems with their drug products, or conditions and practices, unless it receives a complaint such as a report of a serious adverse event or visible contamination. It is critical that compounding facilities avoid the presence of insanitary conditions and identify and remediate any insanitary conditions at their facilities before the conditions result in drug contamination and patient injury.

FDA is issuing this draft guidance to assist compounding facilities in identifying insanitary conditions so that they can implement appropriate corrective actions, and to assist State regulatory agencies in understanding some examples of what FDA considers to be insanitary conditions.

This draft guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the current thinking of FDA on insanitary conditions at compounding facilities. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

#### **II. Electronic Access**

Persons with access to the Internet may obtain the draft guidance at either <http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm> or <http://www.regulations.gov>.

Dated: July 29, 2016.

**Leslie Kux,**

*Associate Commissioner for Policy.*

[FR Doc. 2016-18461 Filed 8-3-16; 8:45 am]

**BILLING CODE 4164-01-P**

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **Food and Drug Administration**

[Docket No. FDA-2016-N-0544]

#### **Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; National Direct-to-Consumer Advertising Survey**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.